Microbiome specialist Enterobiotix Ltd. has reported positive results for the phase Ib trial of its EBX-102 fecal microbiota therapy in patients with stable liver cirrhosis. The placebo-controlled study involved first-in-human dosing with the company’s encapsulated oral formulation of microbiota derived from the stools of healthy donors. After initial dosing, patients were followed up for 12 weeks to assess changes in a range of clinical and blood biomarkers.
The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo.
The first patenting to emerge in the name of Copenhagen, Denmark-based 1Health Gut In Balance ApS (dba Gut In Balance) describes development of an apparatus and system that enables hospitals to produce fecal microbiota transplantation capsules on site, and much more efficiently and cheaply.
South Korea’s Genome & Co. Ltd. (KOSDAQ:314130) shares rose nearly 30% June 3 after it disclosed a potential ₩586.38 billion (US$426 million) licensing deal for its novel antibody-drug conjugate candidate with Switzerland’s Debiopharm International SA.
South Korea’s Genome & Co. Ltd. (KOSDAQ:314130) shares rose nearly 30% June 3 after it disclosed a potential ₩586.38 billion (US$426 million) licensing deal for its novel antibody-drug conjugate candidate with Switzerland’s Debiopharm International SA.
Researchers have identified enzymes in gut microorganisms that could cleave A and B antigens from red blood, transmuting them to O negative cells. This is “a decisive step forward” in the quest to develop a universal donor blood that can be administered to people of any blood group without eliciting a harmful immune response, according to Maher Abou Hachem of the Technical University of Denmark, who co-led the research.
Microbiome specialist Enterobiotix Ltd. has raised £27 million (US$34.2 million) in a series B round as it starts a phase II trial of EBX-102-02 in the treatment of irritable bowel syndrome.
CAR T-cell immunotherapy is designed with different targets depending on the receptors they will bind to. CARs can also contain different tools, like the concept of a Swiss army knife, with several utensils for different tasks. The goal is to make them more effective and durable. During the second session of the Spotlight on Immuno-Oncology conference, “Novel CAR designs and approaches,” Robbie Majzner, of Stanford University, described expanding the main components of CAR T cells to acquire new functions and act on different cell pathways.
Microba Life Sciences Ltd. has started dosing patients in a phase I trial of its gut microbiome-derived therapeutic, MAP-315, for ulcerative colitis, the major form of inflammatory bowel disease (IBD).
